An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A major U.S. obstetrics organization has issued new guidance about using GLP-1 medications during pregnancy. They’re telling doctors and patients to be cautious and generally avoid these drugs when someone is trying to become pregnant, is pregnant, or is breastfeeding. The advice is about minimizing possible risks because the evidence about safety in pregnancy is limited or unclear. GLP-1s (short for glucagon-like peptide-1 receptor agonists) are a class of medications that include well-known names like semaglutide — the active ingredient in Ozempic and Wegovy. In plain terms, these medicines act like a hormone your gut makes after you eat. They help people feel full, slow how fast food leaves the stomach, and can lower blood sugar. Doctors prescribe them for type 2 diabetes and for weight loss. They’re powerful drugs, but they weren’t originally tested widely in pregnant people. The new guidance is based on the limited data available and on potential concerns from animal studies and early human reports. It notes that the studies we have don’t clearly prove safety in pregnancy. Some animal studies showed possible effects on fetal development, and some human case reports suggested a link to problems like low birth weight or birth defects, but the human evidence is small and not definitive. Because of that uncertainty, the organization recommends stopping GLP-1 drugs before trying to conceive and during pregnancy, and using alternative treatments that have clearer safety records for pregnant people. This matters because many people of reproductive age are using GLP-1s for weight loss or diabetes. Someone planning pregnancy, currently pregnant, or breastfeeding needs to know these drugs aren’t recommended right now. For people with diabetes, that doesn’t mean stopping all treatment; doctors can switch to other glucose-control options that are better studied in pregnancy. For those using GLP-1s for weight management, it’s a reminder to discuss family planning and medication timing with a clinician. There are important caveats. The guidance is precautionary: it reflects uncertainty rather than proof of harm. Stopping GLP-1s can have consequences, like weight regain or worse blood sugar control, so any change should be managed with a healthcare provider. We don’t have large, high-quality human studies yet, so recommendations could change as more data come in. Pregnant people or those trying to conceive should not abruptly stop medications without medical advice. Bottom line: A major obstetrics group recommends avoiding GLP-1 drugs around pregnancy because we don’t yet have clear evidence they’re safe, and anyone affected should talk with their clinician about safer alternatives and timing.
Source: Medscape